Clinical Trials
7 trialsNCT06669572 2026-04-15
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04193553 2024-06-18
LENVAGIST
Centre Leon Berard
Phase 2 Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Unknown
NCT04699071 2021-10-21
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
National University Hospital, Singapore
Phase 2 Unknown